FMC (FMC) Stock Forecast & Price Target

FMC is supported by a diversified, pure-play crop protection portfolio and a growing pipeline that should drive share gains and margin improvement across geographies, with ~20 new diamide formulations planned between 2024 and 2033 and about $2B of potential contribution each from AI products and plant health by 2033. The company’s core portfolio and diamides are expected to grow ~5% CAGR through 2026, while new active ingredients should rise to $300M-$400M in 2026 from $200M in 2025 and then increase by ~50% in 2027, helping offset a four-year stretch of lower sales. Fundmentals are also aided by a more constructive ag backdrop, including a ~22% global soybean stocks-to-use ratio versus a 5-year average of ~29%, and management’s actions to reset North America pricing and rebates should reduce channel inventory, volatility, and support a 2027 financial inflection.

FMC is facing a weak fundamental backdrop marked by sharp volume declines, generic-driven price pressure, and aggressive channel destocking that left Q3 underlying EBITDA at about $113M, below consensus, even before the $672M commercial actions hit reported results. Management’s FY26 outlook remains challenged, with adj. EBITDA guided to -$124M to -$104M and free cash flow to -$350M to -$150M, while leverage is still elevated at 6.1x covenant basis against a 6.75x limit, underscoring a stretched balance sheet. Although preliminary 2027/2028 EBITDA frameworks imply an eventual rebound, the combination of weak near-term earnings visibility, low inventory normalization, and continued FX and competitive risks supports a cautious, negative view.